Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Want to cut your energy bills? Here’s how five experts are doing it 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
NEWARK, Calif., March 10, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will host an Analyst and Investor Day on Wednesday, March 23, 2016. The details are as follows:
| Date: Wednesday, March 23, 2016 | |||||
| Time: 9:00 a.m. EDT – 11:30 a.m. EDT (6:00 a.m. PDT – 8:30 a.m. PDT) | |||||
| Location: New York, New York | |||||
| Depomed management: | Jim Schoeneck, President and Chief Executive Officer | ||||
| August Moretti, Senior Vice President and Chief Financial Officer | |||||
| Srinivas Rao, M.D., Ph.D., Chief Medical Officer | |||||
| Scott Shively, Chief Commercial Officer | |||||
Joining Depomed’s senior management team will be:
Joseph V. Pergolizzi, Jr., M.D., Chief Operating Officer, Naples Anesthesia & Physician Associates and an Adjunct Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine. Dr. Pergolizzi is a former Adjunct Faculty member of the Department of Anesthesiology and Pain Medicine at Georgetown University School of Medicine and an Associate Professor in the Department of Pharmacology at Temple University School of Medicine. Dr. Pergolizzi is also a steering committee member of the Food and Drug Administration’s Safe Use Initiative and a consultant to the National Institutes of Health.
Dr. Pergolizzi is the author of over 150 peer reviewed articles, abstracts, platform presentations and book chapters in his areas of interest and expertise. He is an internationally recognized expert in clinical research, pain medicine, anesthesia, internal medicine, pharmacology, regulatory affairs and drug discovery.
Space is limited and attendance is by invitation only. Analysts and institutional investors interested in attending should contact Christopher Keenan of Depomed’s Investor Relations department at [email protected] to request an invitation.
The presentations, as well as the question and answer session, will be simultaneously webcast on the Investor Relations page of Depomed’s website at www.depomed.com. A recording of the webcast and slideshow will be archived for 30 days.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payers we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000
